XML 29 R7.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
$ in Thousands
USD ($)
shares
Common Stock
USD ($)
shares
Additional Paid-In Capital
USD ($)
Accumulated Deficit
USD ($)
Accumulated Other Comprehensive Loss
USD ($)
Total UpHealth, Inc. Stockholders’ Equity
USD ($)
Noncontrolling Interests
USD ($)
Balance at beginning of period (in shares) at Dec. 31, 2019 | shares   0          
Balance at beginning of period at Dec. 31, 2019 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for stock formation (in shares) | shares [1]   50,050,000          
Issuance of common stock for formation [1] 0 $ 5 (5)        
Issuance of common stock to consummate business combinations (in shares) | shares [1]   15,503,000          
Issuance of common stock to consummate business combinations [1] 165,614 $ 2 165,613     165,614  
Issuance of common stock in exchange for a portion of equity method investment (in shares) | shares [1]   4,468,000          
Issuance of common stock in exchange for a portion of equity method investment [1] 57,293   57,293     57,293  
Net loss (2,186)     (2,186)   (2,186)  
Foreign currency translation adjustments $ 0            
Balance at end of period (in shares) at Dec. 31, 2020 | shares 70,021,063 70,021,000 [1]          
Balance at end of period at Dec. 31, 2020 [1] $ 220,721 $ 7 222,900 (2,186) 0 220,721 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss $ (4,829)            
Balance at end of period (in shares) at Sep. 30, 2021 | shares 117,800,000            
Balance at end of period at Sep. 30, 2021 $ 627,085            
Balance at beginning of period (in shares) at Dec. 31, 2020 | shares 70,021,063 70,021,000 [1]          
Balance at beginning of period at Dec. 31, 2020 [1] $ 220,721 $ 7 222,900 (2,186) 0 220,721 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for stock formation (in shares) | shares   26,450,000          
Issuance of common stock for formation 42,965 $ 3 42,962     42,965  
Issuance of common stock to consummate business combinations (in shares) | shares [1]   34,912,000          
Issuance of common stock to consummate business combinations [1] 346,249 $ 3 330,992     330,996 15,253
Merger recapitalization (in shares) | shares   9,471,000          
Merger recapitalization 54,605 $ 1 54,604     54,605  
Issuance of common stock in connection with PIPE (in shares) | shares   3,000,000          
Issuance of common stock in connection with PIPE 27,079   27,079     27,079  
Forward share repurchase agreement (17,000)   (17,000)     (17,000)  
Issuance of common stock for debt conversion (in shares) | shares   200,000          
Issuance of common stock for debt conversion 1,879   1,879     1,879  
Purchase consideration adjustment 677   677     677  
Issuance of common stock in connection with equity incentive plans, net (in shares) | shares   225,000          
Issuance of common stock in connection with equity incentive plans, net 319   319     319  
Stock-based compensation 1,048   1,048     1,048  
Net loss (340,897)     (341,023)   (341,023) 126
Foreign currency translation adjustments $ (3,802)       (3,802) (3,802)  
Balance at end of period (in shares) at Dec. 31, 2021 | shares 144,278,969 144,279,000          
Balance at end of period at Dec. 31, 2021 $ 333,843 $ 14 665,461 (343,209) (3,802) 318,464 15,379
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exchange ratio 10.28            
Balance at end of period (in shares) at Dec. 31, 2021 | shares 144,278,969 144,279,000          
Balance at end of period at Dec. 31, 2021 $ 333,843 $ 14 $ 665,461 $ (343,209) $ (3,802) $ 318,464 $ 15,379
[1] (1) Amounts as of March 31, 2021 and before that date differ from those published in prior consolidated financial statements as they were retrospectively adjusted as a result of the accounting for the Business Combinations (as defined below in Note 1). Specifically, the number of common shares outstanding during periods before the Business Combinations are computed on the basis of the number of common shares of UpHealth Holdings (accounting acquiror) during those periods multiplied by the exchange ratio established in the stock purchase agreement (1.00 UpHealth Holdings shares converted to 10.28 GigCapital2 shares). Common stock and additional paid-in capital were adjusted accordingly.